Cognition Therapeutics says FDA aligned on Phase 3 zervimesine trial design in DLB
Cognition Therapeutics said the FDA has aligned with it on key elements of a Phase 3 study of zervimesine in dementia with Lewy bodies, including patient selection, dose, duration and endpoints. The company is now completing a protocol for the planned registrational study, which the filing describes as covering a disease with no approved treatments. The filing contains no financial figures, so the update's effect on shareholders depends on the trial's future results and regulatory path.
Key points
- Planned study will randomize participants with mild-to-moderate DLB to 100 mg once-daily oral zervimesine or placebo for nine months
- Primary endpoint is the NPI-2 neuropsychiatric inventory measuring hallucinations and delusions
- Key secondary endpoint is the ADCS-ADL scale, which evaluates effects on daily function
- The announcement was made October 22, 2026, in a press release filed as Exhibit 99.1
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 22, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.